Strata Critical Medical (SRTA) AI Stock Analysis

• Market Cap: $494.88M
• Dividend Yield: N/A
• Average Volume (3M): 804.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: -5.40%
• EPS Growth: 63.20%
• Country: US
• Employees: 310
• Sector: Industrials
• Sector Strength: 72
• Industry: Airlines, Airports & Air Services
• EPS (TTM): -0.12
• Shares Outstanding: 86,366,520
• 10 Day Avg. Volume: 879,308
• 30 Day Avg. Volume: 804,810
• PEG Ratio: 0.22
• Price to Book (P/B): 1.48
• Price to Sales (P/S): 1.32
• P/FCF Ratio: -9.27
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 1.74
• Enterprise Value/Gross Profit: 7.38
• Enterprise Value/Ebitda: -15.83
• 1Y Price Target: $9.63
• Price Target Upside: 67.98% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.41
• Revenue Forecast (FY): $270.00M

• Rating: 57 Neutral
• Price Target: $6.00 ▲(4.71% Upside)

Strata Critical Medical's overall score is driven by financial challenges and valuation concerns, partially offset by positive earnings call insights and strategic corporate events.

Positive Factors

Low leverage

Extremely low leverage and a positive 17% ROE provide durable financial flexibility, reducing bankruptcy risk and enabling the company to fund operations, M&A or working capital needs without heavy interest burdens. This supports stability and strategic optionality over months.

Rising EBITDA margins

Sustained improvement in segment adjusted EBITDA and medical margins indicates better unit economics and operational leverage in core services. Higher margins improve free cash flow potential and resilience to volume swings, supporting reinvestment and deleveraging over the medium term.

Strategic refocus and M&A

Transformational transactions and rebranding concentrate the company on organ recovery and logistics, aligning resources with higher-growth, specialized services. This strategic focus can deliver scale, cross-selling and margin synergies that persist beyond short-term cycles.

Negative Factors

Declining revenue trend

A sustained negative revenue trend undermines scale economics and can erode competitive position. If top-line decline persists, it pressures margins, limits investment capacity, and raises reliance on acquisitions or one-off items to meet growth targets over the next several quarters.

Negative operating cash flow

Negative operating cash flow despite reported net income signals poor cash conversion and working-capital stress. Volatile free cash flow reduces ability to self-fund growth, increases refinancing risk, and may force external financing or curbs on investments over the medium term.

Ongoing litigation provision

An active legal provision tied to the go-public transaction creates uncertain, potentially material cash and reputational exposure. Legal outcomes can impose multi-period costs, distract management, and complicate partnerships or financing, reducing operational predictability.

Strata Critical Medical Business Overview & Revenue Model

Company Description

Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

How the Company Makes Money

Strata Critical Medical generates revenue through multiple streams, primarily focusing on the sales of its medical devices and related software solutions to hospitals, healthcare providers, and emergency medical services. The company employs a direct sales force and leverages distribution partnerships to reach a broader market. Additionally, SRTA earns income through service contracts for maintenance and support of its devices, as well as from training programs for healthcare professionals on the effective use of its products. Strategic partnerships with healthcare institutions and research organizations also contribute to revenue through collaborative projects and grants aimed at advancing medical technology.

Strata Critical Medical Financial Statement Overview

Summary

Strata Critical Medical faces financial challenges with declining revenue and negative cash flow, despite a positive net profit margin and low leverage.

Income Statement

Strata Critical Medical shows a mixed performance in its income statement. The company has a declining revenue trend with a negative revenue growth rate of -10.06% in the TTM, indicating challenges in maintaining sales momentum. Despite a positive net profit margin of 17.65% in the TTM, the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies. The gross profit margin is relatively stable, but the overall profitability is hindered by high operational costs.

Balance Sheet

The balance sheet of Strata Critical Medical is relatively stable with a low debt-to-equity ratio of 0.012, indicating low leverage and financial risk. The return on equity is positive at 17.05% in the TTM, showing effective use of equity to generate profits. However, the equity ratio is not explicitly calculated, but the overall asset base seems adequately supported by equity.

Cash Flow

Cash flow analysis reveals significant challenges for Strata Critical Medical. The company has a negative operating cash flow and free cash flow, with a high free cash flow growth rate of 142.19% in the TTM, indicating volatility. The operating cash flow to net income ratio is negative, suggesting cash flow issues despite reported net income. The free cash flow to net income ratio is positive, indicating some cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	228.76M	248.69M	225.18M	146.12M	50.53M	23.43M
Gross Profit	53.92M	58.92M	42.12M	22.27M	10.52M	2.33M
EBITDA	-25.14M	-27.96M	-61.01M	-69.87M	-23.50M	-9.83M
Net Income	40.39M	-27.31M	-56.08M	-27.26M	-40.05M	-10.16M
Balance Sheet
Total Assets	335.08M	256.68M	294.94M	325.02M	335.88M	17.71M
Cash, Cash Equivalents and Short-Term Investments	75.92M	127.14M	166.14M	192.08M	281.97M	12.16M
Total Debt	3.47M	9.32M	24.52M	18.33M	716.00K	1.89M
Total Liabilities	52.08M	34.74M	60.64M	50.54M	44.51M	6.63M
Stockholders Equity	283.00M	221.94M	234.30M	274.49M	291.37M	11.08M
Cash Flow
Free Cash Flow	-54.64M	-35.51M	-34.46M	-37.86M	-16.42M	-11.20M
Operating Cash Flow	-40.59M	-2.52M	-32.35M	-37.13M	-15.62M	-10.82M
Investing Cash Flow	55.46M	-1.02M	17.09M	79.34M	-321.34M	-377.00K
Financing Cash Flow	-12.81M	-5.76M	-76.00K	-1.08M	332.26M	1.18M

Strata Critical Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.73
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Positive. The current price of 5.73 is above the 20-day moving average (MA) of 5.36, above the 50-day MA of 4.90, and above the 200-day MA of 4.27, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 64.95 is Neutral, neither overbought nor oversold. The STOCH value of 79.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTA.

Strata Critical Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNCY	69 Neutral	$938.65M	16.87	9.99%	―	4.27%	28.47%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
ASLE	57 Neutral	$364.27M	58.44	1.35%	―	-1.64%	1966.67%
SRTA	57 Neutral	$494.88M	-23.87	-10.33%	―	-5.40%	63.20%
FLYX	48 Neutral	$349.21M	-3.09	―	―	―	―
SRFM	48 Neutral	$159.61M	-0.92	―	―	-8.51%	82.15%

Strata Critical Medical Corporate Events

Strata Critical Medical Expands Board with New Director

On December 2, 2025, Strata Critical Medical, Inc. expanded its Board of Directors by appointing William L. Cook, III as a Class I director, effective immediately, with his term expiring at the 2027 annual meeting of stockholders. Mr. Cook, who is deemed independent under Nasdaq rules, will also serve on the Compensation and Nominating and Corporate Governance Committees. His extensive healthcare experience is expected to aid Strata in scaling its organ recovery and logistics platform across the country, enhancing its mission to increase organ availability for transplants and explore broader medical sector services.

The most recent analyst rating on (SRTA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Strata Critical Medical stock, see the SRTA Stock Forecast page.